On Thursday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: STMicroelectronics NV (ADR) (NYSE:STM), Endeavour Silver Corp (NYSE:EXK), Hecla Mining Company (NYSE:HL), MEI Pharma Inc (NASDAQ:MEIP)
STMicroelectronics NV (ADR) (NYSE:STM)’s shares dwindled -3.73%, and closed at $9.04. The stock volatility for the week is 3.18M%, while for the month remained 1.89M%. The company holds consensus target price of $9.37.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed 0.15 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 125.00% and Annual EPS growth for the past 5 years is considered as 16.10%.
The mean recommendation of analysts for this stock is 2.30. (where 1=Buy, 5=Sale).
STMicroelectronics N.V. designs, develops, manufactures, and markets various semiconductor integrated circuits and discrete devices worldwide. The company offers a range of semiconductor products, counting discrete and standard commodity components, application-specific integrated circuits, full-custom devices and semi-custom devices, micro-electro-mechanical systems, microcontrollers, sensors, digital consumer products, imaging products, memory products, media application processors, and application-specific standard products for analog, digital, and mixed-signal applications, in addition to silicon chips and smartcards.
Endeavour Silver Corp (NYSE:EXK), declined -3.72%, and closed at $2.07. The company holds the market capitalization of $219.61M. For the last twelve months, the stock was able to keep return on equity at -30.30%, while return on assets at -21.90%, in response to its return on investment at -31.50%. Its 20-day moving average gained 3.71%, below 50-day moving average of -11.95%, below 200-day moving average of -45.40% from the latest market price of $2.07. The mean recommendation of analysts for this stock is 3.00.(where 1=Buy, 5=Sale).
Endeavour Silver Corp. engages in the evaluation, attainment, exploration, development, and exploitation of precious metal properties in Mexico and Chile. It produces silver-gold from its underground mines. The company primarily holds interests in silver mining projects in Mexico comprising the Guanacevi mine in the Durango state; and the Bolaitos and El Cubo mines in the Guanajuato state. It also has interests in certain exploration properties in Mexico and Chile, counting Guadalupe Y Calvo exploration project in Chihuahua, Mexico; and the San Sebastian project located in Jalisco, Mexico, in addition to an option to purchase a 75% interest in the El Inca properties located in Chile. In addition, Endeavour Silver Corp. holds interests in the La Bufa gold-silver property comprising 4 mining concessions totaling 2,311.1 hectares in Mexico.
Hecla Mining Company (NYSE:HL), dipped -3.72%, and closed at $3.11. The company has the market capitalization of $1.19B. The beta value of the stock is 0.91. On the other hand the stock’s volatility for the week is 4.84%, and for the month is 5.17%. The stock’s price to book ratio is 2.29, however price to sale ratio is 0.82. Analyst’s mean recommendation regarding this stock is 3.20. (where 1=Buy, 5=Sale).
Hecla Mining Company, together with its subsidiaries, discovers, attains, develops, produces, and markets precious and base metal deposits worldwide. The company offers unrefined gold and silver bullion bars to precious metals traders; and lead, zinc, and bulk concentrates to custom smelters and brokers. It owns 100% interests in the Greens Creek mine located on Admiralty Island in Southeast Alaska; the Lucky Friday unit located in the Coeur d’Alene mining district in northern Idaho; and the Casa Berardi mine located in the Abitibi region of north-western Quebec, Canada. The company was founded in 1891 and is based in Coeur d’Alene, Idaho.
MEI Pharma Inc (NASDAQ:MEIP), dropped -3.68%, and closed at $1.83, hitting new 52-week low of $1.79. The stock has price to book ratio of 0.59, however, price to cash ratio is 0.77. With recent decline, the year-to-date (YTD) performance reflected a -57.14% decline below last year. During the past month the stocks lose -67.61%, bringing three-month performance to -51.72% and six-month performance to -73.52%. The mean recommendation of analysts for this stock is 1.40. (where 1=Buy, 5=Sale).
MEI Pharma, Inc., an oncology company, focuses on the clinical development of novel therapies for the treatment of cancer. The company’s lead drug candidate is Pracinostat, an orally accessible histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia. Its clinical development pipeline also comprises ME-344, an isoflavone-derived mitochondrial inhibitor drug candidate that is in Phase Ib trial to treat lung and ovarian cancer; and PWT143, an oral inhibitor of phosphatidylinositide 3-kinase, which is in pre-clinical stage for the treatment of cancer. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a partner of Novogen Limited.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
